Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy of Β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules Nfҡb, Il-8 and Cd49d Using Healthy Donor Pbmc Publisher Pubmed



Khalatbari A1 ; Mahdavi M2 ; Jafarnezhad F3 ; Afraei S1 ; Zavareh FT1 ; Aghazadeh Z1 ; Ghaderi A4 ; Mirshafiey A1, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
  3. 3. Department of Immunology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. Department of internal medicine, Hematology and Medical oncology Ward, Cancer Research Center. Cancer Institute, Imam Khomeini hospital complex, Tehran University of Medical Science, Tehran, Iran
  5. 5. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Current Drug Discovery Technologies Published:2020


Abstract

This investigation evaluates the pro-apoptotic and anti-inflammatory effects of β-D-mannuronic acid [M2000] compared to diclofenac, based on gene expression involved in apoptosis and inflammation process [including Bcl2, NFκB, IL-8 and Cd49d] in Peripheral Blood Mononu-clear Cells [PBMCs] of healthy donors under exvivo conditions. The venous blood samples of twelve healthy volunteers with aged 25-60 years were collected in heparinized tubes. The healthy volunteers were selected from no smoking group and without using illicit drugs and suffering from diabetes. The PBMCs were separated and divided into untreated and treated groups. The PBMCs of each sample were cultured in 5 wells of culture plate, so that the first well consist-ed of 2×106 cells exposed by LPS-EB [1µg/ml] to stimulate PBMCs and absence of M2000 [un-treated well]. The second, third, fourth and fifth wells containing 2×106 cells/well and LPS-EB, af-ter 4 hours incubation at 37ºC, received 5, 25 and 50 µg/well of M2000 and 5 µg/well of diclo-fenac, respectively as treated group. The PBMCs were separated and RNAs were then extracted and cDNAs synthesized and gene expression levels were assessed by qRT-PCR. Furthermore, we studied whether M2000 is able to facilitate apoptosis in PBMCs. Our findings represent that the high dose of M2000 could significantly decrease the expression level of NFκB gene compared to untreated group (p < 0.0002). On the other hand, no significant change was observed in treated cells with diclofenac. All doses of M2000 could significantly augment apoptosis compared to untreated group [p < 0.0001]. Addi-tionally, we observed the same apoptotic effects between the medium dose of M2000 and diclo-fenac. Besides, no significant reduction was shown in expression levels of IL8, Bcl2 and Cd49d genes in all doses of M2000 and diclofenac compared to untreated group. This experiment demon-strates M2000 as a new effective NSAID with immunosuppressive characteristics capable of stimu-lating apoptosis through lowering expression levels of NFκB gene, which might be probably consid-ered as an appropriate drug for reducing the risk of developing inflammatory diseases and cancer. © 2020 Bentham Science Publishers.
5. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
Experts (# of related papers)
Other Related Docs
12. Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study, Iranian Journal of Allergy# Asthma and Immunology (2022)
40. The Effect of Β-D-Mannuronic Acid in Animal Model of Epilepsy, Natural Product Communications (2020)
44. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
47. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications, Iranian Journal of Allergy# Asthma and Immunology (2018)